Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine

NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology ...

author_avatar
NASDAQ Market News

Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania

Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech Oy’s Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech OyCompany release February 21, 2018 at 3.30 pm EET FIT Biotech Oy's ...

author_avatar
NASDAQ Market News